Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 1
2000 2
2003 5
2004 2
2005 1
2007 5
2008 4
2009 2
2010 2
2012 2
2013 3
2014 1
2015 2
2016 2
2017 2
2018 1
2019 6
2020 2
2021 6
2022 4
2023 2
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, Hájek R, Liu Z, Minarik J, Moreau P, Romejko-Jarosinska J, Spicka I, Vorobyev VI, Besemer B, Ishida T, Janowski W, Kalayoglu-Besisik S, Parmar G, Robak P, Zamagni E, Goldschmidt H, Martin TG, Manier S, Mohty M, Oprea C, Brégeault MF, Macé S, Berthou C, Bregman D, Klippel Z, Orlowski RZ; IMROZ Study Group. Facon T, et al. Among authors: kalayoglu besisik s. N Engl J Med. 2024 Oct 31;391(17):1597-1609. doi: 10.1056/NEJMoa2400712. Epub 2024 Jun 3. N Engl J Med. 2024. PMID: 38832972 Clinical Trial.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Independent risk factors for COVID-19-associated coagulopathy.
Tor YB, Ozbalak M, Kalayoglu-Besisik S, Aksoy E, Cagatay AA, Gul A, Erelel M, Senkal N, Medetalibeyoglu A, Kose M, Tukek T. Tor YB, et al. Among authors: kalayoglu besisik s. Eur Rev Med Pharmacol Sci. 2023 Aug;27(16):7851-7860. doi: 10.26355/eurrev_202308_33440. Eur Rev Med Pharmacol Sci. 2023. PMID: 37667962 Free article.
Myelomatous Pleural Effusion: A Rare Involvement in Myeloma.
Alkan O, Tiryaki TO, Kalayoglu-Besisik S. Alkan O, et al. Among authors: kalayoglu besisik s. J Med Cases. 2020 Mar;11(3):55-56. doi: 10.14740/jmc3428. Epub 2020 Mar 26. J Med Cases. 2020. PMID: 34434362 Free PMC article.
Recommendations for the Treatment of Invasive Fungal Infections in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-1).
Akan H, Ongören Aydın S, Saltoğlu N, Cağatay A, Akalın H, Arat M, Ali R, Kalayoğlu-Beşışık S, Demir AM. Akan H, et al. Among authors: kalayoglu besisik s. Turk J Haematol. 2014 Jun;31(2):111-20. doi: 10.4274/tjh.2014.0103. Epub 2014 Jun 10. Turk J Haematol. 2014. PMID: 25035667 Free PMC article. Review.
61 results